Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 07, 2022

SELL
$8.55 - $111.89 $19,169 - $250,857
-2,242 Closed
0 $0
Q4 2019

Feb 10, 2020

BUY
$66.49 - $137.73 $149,070 - $308,790
2,242 New
2,242 $214,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $102M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Silvant Capital Management LLC Portfolio

Follow Silvant Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silvant Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silvant Capital Management LLC with notifications on news.